Lumos Diagnostics is striving to become the leader in rapid point-of-care tests to distinguish between viral and bacterial ...

Egypt - The Egyptian Cabinet approved several key decisions on Tuesday, including a draft resolution to establish the ...

General Matter says it will use a novel, scalable, cost-competitive technology to address a "commercial bottleneck" in the US ...

Q1 2025 Earnings Call Transcript April 29, 2025 NeoGenomics, Inc. misses on earnings expectations. Reported EPS is $-0.20352 ...

Prime Medicine’s modular editing tech may lower off-target risk, but key data and funding milestones remain ahead. Find out ...

Los Angeles-based start-up General Matter in a post on X claims that it will revive nuclear fuel production in ...

Assay differences can result from the inherent assay design (i.e. competitive versus non-competitive immunoassay) as well as the signal used. Assay differences can result from the use of different ...

Nautilus Biotechnology, Inc. ( NASDAQ: NAUT) Q1 2025 Earnings Conference Call April 29, 2025 8:30 AM ET Ji-Yon Yi - Head, Investor Relations Sujal Patel - Co-Founder & Chief Executive Officer Parag ...

The recent NHANES III United States survey of ~17,000 subjects without apparent thyroid disease, reported detectable TPOAb levels in 12 % of subjects using a competitive immunoassay method.

According to GlobalData, these tariffs are expected to impact all 510(k)-approved medical devices manufactured outside of the ...